Wells upgrades uniQure on ‘high likelihood of success’ in Huntington’s

Wells Fargo analyst Yanan Zhu upgraded uniQure (QURE) to Overweight from Equal Weight with a price target of $35, up from $14. With FDA alignment reached on the accelerated approval pathway for AMT-130, the major concern is addressed, the analyst tells investors in a research note. On the question of approvability, Wells sees a “high likelihood of success” given precedent of Skysona accelerated approval on an intermediate clinical endpoint and external control. The firm upgraded uniQure after increasing its probability of success for its Huntington’s disease program to 75% from 10%.